Main information

  • Trade name:
  • Doxyveto 500 mg/g Powder for Use in Drinking Water for Chickens
  • Available from:
  • VMD NV
  • Pharmaceutical form:
  • Powder for use in drinking water
  • Prescription type:
  • POM-V - Prescription Only Medicine – Veterinarian
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug



  • Available in:
  • Doxyveto 500 mg/g Powder for Use in Drinking Water for Chickens
    United Kingdom
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • Chickens
  • Therapeutic area:
  • Antimicrobial

Other information



  • Source:
  • VMD - Veterinary Medicines Directorate
  • Authorization status:
  • Authorized
  • Authorization number:
  • 19968/4001
  • Authorization date:
  • 29-11-2011
  • Last update:
  • 21-12-2016

Summary of Product characteristics


Revised: November 2016

AN: 00269/2016



Doxyveto 500 mg/g powder for use in drinking water for chickens


One gram contains:

Active substance:

Doxycycline hyclate 500 mg


For the full list of excipients, see section 6.1.


Powder for use in drinking water

Homogeneous, fine, yellow powder.


4.1 Target species

Non-egg laying chickens.

4.2 Indications for use, specifying the target species

Treatment of the following specified infections of the respiratory tract and alimentary

tract caused by micro-organisms susceptible to doxycycline.

Non-egg laying chickens:

Infections of the respiratory tract caused by Mycoplasma spp, Escherichia coli,

Avibacterium paragallinarum and Bordetella avium.

Enteritis caused by Clostridium perfringens and Clostridium colinum.

4.3 Contraindications

Do not use in cases of hypersensitivity to tetracyclines or any of the excipients.

Do not administer to animals with severe liver or kidney insufficiency.

4.4 Special warnings for each target species


4.5 Special precautions for use

Special precautions for use in animals

Due to variability (time, geographical) in susceptibility of bacteria to doxycycline,

bacteriological sampling and susceptibility testing of micro-organisms from diseased

animals on farm are highly recommended.

A high resistance rate of E.coli isolated from chickens, against tetracyclines has been

documented. Therefore the product should be used for the treatment of infections

caused by E.coli only after susceptibility testing has been carried out.

Page 1 of 5

Revised: November 2016

AN: 00269/2016

As eradication of the target pathogen may not be achieved, medication should

therefore be combined with good management practices e.g. good hygiene, proper

ventilation, no overstocking.

Special precautions to be taken by the person administering the veterinary medicinal

product to animals

This product may cause contact dermatitis and/or hypersensitivity reactions if contact

is made with the skin or eyes (powder and solution), or if the powder is inhaled.

People with known hypersensitivity to tetracyclines should not handle the product.

Wear impermeable gloves (e.g. rubber or latex) and an appropriate dust mask (e.g. a

disposable half-mask respirator conforming to European Standard EN 149 (FFP2) or

a non-disposable respirator to European Standard EN 140 with a filter to EN 143)

when applying the product.

Do not smoke, eat or drink while handling the product. In the event of eye or skin

contact, rinse the affected area with large amounts of clean water and if irritation

occurs, seek medical attention. Wash hands and contaminated skin immediately after

handling the product.

If you develop symptoms following exposure such as skin rash, you should seek

medical advice and show this warning to the physician. Swelling of the face, lips or

eyes, or difficulty with breathing are more serious symptoms and require urgent

medical attention.

4.6 Adverse reactions (frequency and seriousness)

None known.

4.7 Use during pregnancy, lactation or lay

Laying birds:

Do not use in birds in lay and within 4 weeks before the onset of the laying period.

4.8 Interaction with other medicinal products and other forms of interaction

Do not administer in combination with bactericidal antibiotics, such as penicillins and


Doxycycline absorption may be reduced by the presence of high quantities of

calcium, iron, magnesium or aluminium in the diet.

4.9 Amounts to be administered and administration route

Non-egg laying chicken: 25 mg doxycycline hyclate per kg bodyweight per day,

corresponding to 50 mg of product per kg bodyweight, per day for 3-5 days.

Route of administration: For the administration through the drinking water, the exact

daily amount of product should be calculated, based on the recommended dose, and

the number and weight of the birds to be treated, according to the following formula:

Mg product per litre drinking water =

Mg product/kg bodyweight/day x mean bodyweight (kg) of birds to be treated

Mean daily water consumption (litre) per animal

To ensure a correct dosage, bodyweight should be determined as accurately as

possible to avoid underdosing. The uptake of medicated water depends on the

clinical conditions of the birds and the concentration of doxycycline should be

adjusted accordingly. The daily amount is to be added to the drinking water such that

all medication will be consumed in 24 hours. Medicated drinking water should be

Page 2 of 5

Revised: November 2016

AN: 00269/2016

freshly prepared every 24 hours. It is recommended to prepare a concentrated pre-

solution – approximately 100 grams product per litre drinking water – and to dilute

this further to therapeutic concentrations if required. Alternatively, the concentrated

solution can be used in a proportional water medicator. Medicated water should be

the only drinking source.

Use appropriately and properly calibrated dosing equipment.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

Doxycycline has a high therapeutic index. The normal dose for oral use is 25 mg/kg

bodyweight, where the LD50 for the most sensitive animal species is 1700 mg/kg

bodyweight after oral administration.

4.11 Withdrawal period(s)

Meat and Offal: 5 days.

Not authorised for use in birds producing eggs for human consumption.


Pharmacotherapeutic group: Antibiotics.

ATCvet code: QJ01AA02.

5.1 Pharmacodynamic properties

Doxycycline is a broad spectrum antibiotic. It inhibits the intracellular bacterial protein

synthesis by binding on the 30S ribosomal subunits. As such, the access of

aminoacetyl-tRNA to the receptor location of the mRNA-ribosomal complex is

blocked. As a result the linkage of amino acids to the forming peptide chain is

inhibited. Doxycycline inhibits bacteria, Mycoplasmas, Chlamydia, Rickettsia, and

certain Protozoa.

Four resistance mechanisms acquired by microorganisms against tetracyclines in

general have been reported: decreased accumulation of tetracyclines (decreased

permeability of the bacterial cell wall and active efflux), protein protection of the

bacterial ribosome, enzymatic inactivation of the antibiotic and rRNA mutations

(preventing the tetracycline binding to ribosome). Tetracycline resistance is usually

acquired by means of plasmids or other mobile elements (e.g. conjugative

transposons). Cross resistance between tetracyclines has also been described. Due

to the greater liposolubility and greater facility to pass through cell membranes (in

comparison to tetracycline), doxycycline retains a certain degree of efficacy against

microorganisms with acquired resistance to tetracyclines.

5.2 Pharmacokinetic particulars

Doxycycline is rapidly and almost fully absorbed from the intestine. Presence of food

in the intestine has no influence on the absorption of doxycycline. The distribution of

doxycycline throughout the body and the penetration in most tissues is good.

Tetracyclines are virtually not metabolised after absorption. In contrast to other

tetracyclines, doxycycline is primarily excreted via the faeces.

Steady state plasma concentrations of 2.05 ± 0.47 µg/ml were reached within 6 hours

after start of the medication and varied between 1.28 and 2.18 µg/ml with a dosage

of 25 mg/kg body weight during 5 days.

Page 3 of 5

Revised: November 2016

AN: 00269/2016


6.1 List of excipients

Citric Acid Anhydrous.

Lactose Monohydrate.

6.2 Incompatibilities

None known.

6.3 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 3 years.

Shelf life after first opening the immediate packaging: 28 days.

Shelf life after reconstitution according to directions: 24 hours.

6.4. Special precautions for storage

This veterinary medicinal product does not require any special storage conditions.

6.5 Nature and composition of immediate packaging

Packs of 100 g and 1 kg bags formed in a polyester/aluminium foil/polyethylene


Not all pack sizes may be marketed.

6.6 Special precautions for the disposal of unused veterinary medicinal

product or waste materials derived from the use of such products

Any unused veterinary medicinal product or waste materials derived from such

veterinary medicinal product should be disposed of in accordance with local



V.M.D. n.v.

Hoge Mauw 900

2370 Arendonk



Vm 19968/4001


29 November 2011

Page 4 of 5

Revised: November 2016

AN: 00269/2016


November 2016


To be supplied only on veterinary prescription.

16 November 2016

Page 5 of 5

There are no safety alerts related to this product.

There are no news related to this product.